DE3783007D1 - 9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate. - Google Patents

9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate.

Info

Publication number
DE3783007D1
DE3783007D1 DE8787201933T DE3783007T DE3783007D1 DE 3783007 D1 DE3783007 D1 DE 3783007D1 DE 8787201933 T DE8787201933 T DE 8787201933T DE 3783007 T DE3783007 T DE 3783007T DE 3783007 D1 DE3783007 D1 DE 3783007D1
Authority
DE
Germany
Prior art keywords
production
hydroxysteroids
alpha
dehydro derivatives
dehydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787201933T
Other languages
English (en)
Other versions
DE3783007T2 (de
Inventor
Jacobus Nicolaas Maria Batist
Arthur Friedrich Marx
Zoest Willem Johan Van
Jagdish Chander Kapur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of DE3783007D1 publication Critical patent/DE3783007D1/de
Publication of DE3783007T2 publication Critical patent/DE3783007T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0014—Androstane derivatives substituted in position 17 alfa, not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
DE8787201933T 1986-10-10 1987-10-09 9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate. Expired - Lifetime DE3783007T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP86201754 1986-10-10
EP87201340 1987-07-13

Publications (2)

Publication Number Publication Date
DE3783007D1 true DE3783007D1 (de) 1993-01-21
DE3783007T2 DE3783007T2 (de) 1993-07-01

Family

ID=26103306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787201933T Expired - Lifetime DE3783007T2 (de) 1986-10-10 1987-10-09 9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate.

Country Status (19)

Country Link
US (2) US5352809A (de)
EP (1) EP0263569B1 (de)
JP (1) JPH0826062B2 (de)
KR (1) KR960010793B1 (de)
CN (2) CN1035182C (de)
AU (1) AU607948B2 (de)
CA (1) CA1334844C (de)
DE (1) DE3783007T2 (de)
DK (1) DK175438B1 (de)
ES (1) ES2052550T3 (de)
FI (1) FI95710C (de)
GR (1) GR3006576T3 (de)
HU (2) HU204063B (de)
IE (1) IE61985B1 (de)
IL (1) IL84135A (de)
NO (1) NO174748C (de)
NZ (1) NZ222103A (de)
PT (1) PT85891B (de)
WO (1) WO1988002753A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960010793B1 (ko) * 1986-10-10 1996-08-08 루쎌 위클라프 소시에떼 아노님 9-알파-히드록시 스테로이드 및 그의 제조방법
US4921638A (en) * 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
EP0322081B1 (de) * 1987-12-23 1992-12-16 Roussel-Uclaf Mikrobiologische Herstellung von 9-Alpha-hydroxy-17-keto-steroiden
US5298398A (en) * 1987-12-23 1994-03-29 Gist-Brocades Nv Preparation of 9-α-hydroxy-17-keto steroids using Mycobacterium species CBS 482.86
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
DE69032648T2 (de) * 1989-07-07 1999-04-08 Endorecherche Inc Androgenderivate zur Hemming der Aktivität der Sexualsteroide
KR920703065A (ko) * 1989-07-07 1992-12-17 원본미기재 안드로겐 관련질병의 치료방법
ZA909444B (en) * 1989-11-27 1991-08-28 Schering Corp Process for dehydrating corticosteroid intermediates
JPH05501115A (ja) * 1990-03-27 1993-03-04 シェリング・コーポレーション ９α―ヒドロキシ　ステロイドの脱水法
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
AU3582393A (en) * 1992-01-28 1993-09-01 Schering Corporation Novel steroid intermediates and processes for their preparation
HUT71514A (en) * 1992-05-21 1995-12-28 Endorecherche Inc Inhibitors of testosterone 5 alfa-reductase activity and pharmaceutical compositions containing the same
FR2692580B1 (fr) * 1992-06-19 1994-08-26 Roussel Uclaf Nouveau Procédé de préparation d'un composé stéroïde DELTA9 (11).
EP0759928A1 (de) * 1994-05-09 1997-03-05 The Upjohn Company Verfahren zur herstellung von 17-beta-cyano-3-ethoxy-17alpha hydroxy-6-methylandrostan
FR2720747B1 (fr) * 1994-06-02 1996-07-12 Roussel Uclaf Nouveau procédé de préparation d'un stéroïde 16béta-méthyl et nouveaux intermédiaires.
EP0973791B1 (de) 1995-12-11 2007-06-20 G.D. Searle LLC. Verfahren zur herstellung einer epoxyverbindung
BR9714510A (pt) 1996-12-11 2000-11-28 Searle & Co Processo e preparo de esteróides de 9,11-époxi e intermediários úteis dos mesmos
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
US6610917B2 (en) * 1998-05-15 2003-08-26 Lester F. Ludwig Activity indication, external source, and processing loop provisions for driven vibrating-element environments
AU4093799A (en) 1998-05-22 1999-12-13 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
AU2003220251A1 (en) * 2002-03-22 2003-10-13 Pharmacia Corporation C-17 spirolactonization and 6,7 oxidation of steroids
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
JP2008539047A (ja) 2005-04-28 2008-11-13 プロテウス バイオメディカル インコーポレイテッド ファーマインフォーマティックスシステム
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
CN102516345B (zh) * 2011-11-01 2014-11-26 上海优拓医药科技有限公司 醋酸乌利司他及其关键中间体的制备方法
ES2576231T3 (es) * 2011-12-23 2016-07-06 Crystal Pharma S.A.U Proceso para alquinilar 17-cetoesteroides 16-sustituidos
EP3309166A3 (de) * 2013-01-23 2018-08-22 Sphaera Pharma Pvt. Ltd. 11-beta-hydroxy-steroiden zur verwendung bei einer mitochondrien-biogenese und krankheiten im zusammenhang mit mitochondriendysfunktion oder -abreicherung
CN103361394B (zh) * 2013-08-07 2016-08-17 中国科学院上海高等研究院 利用微生物转化制备9α-羟基-雄烯二酮的方法
EP3171855B1 (de) 2014-07-23 2020-08-26 Sphaera Pharma Pvt. Ltd. 11.beta.-hydroxysteroid-4-aza-verbindungen, zusammensetzungen und verwendungen davon
CN105440094B (zh) * 2015-11-27 2017-08-25 江苏佳尔科药业集团有限公司 地塞米松中间体的制备方法
CN109369759A (zh) * 2018-11-22 2019-02-22 湖南原野医药有限公司 氢化可的松中间体17β-氰基甾体化合物的合成方法
CN109734762B (zh) * 2018-12-05 2020-04-17 郑良彬 一锅法合成16-β甲基甾体化合物的方法
CN111320665A (zh) * 2020-03-04 2020-06-23 台州仙琚药业有限公司 制备17β-氰基-17α-羟基-9-去氢雄烯二酮的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA565369A (en) * 1958-10-28 P. Graber Robert 9,11-dihydroxy steroids and processes for preparing the same
US2837545A (en) * 1957-04-29 1958-06-03 American Cyanamid Co 9alpha, 11beta, 16alpha, 17alpha, 21-penta-hydroxy-4-pregnene-3, 20 dione, its 16, 21 diesters and process of preparing the above compounds
US2840580A (en) * 1957-05-24 1958-06-24 Olin Mathieson 9alpha-hydroxy steroids
US4035236A (en) * 1975-10-24 1977-07-12 The Upjohn Company Process for preparing 9α-hydroxyandrostenedione
US4102907A (en) * 1977-03-07 1978-07-25 The Upjohn Company Desulfinylation process for preparing androsta-4,9(11)-diene-3,17-dione
US4397947A (en) * 1981-06-12 1983-08-09 G. D. Searle & Co. Microbial process for 9α-hydroxylation of steroids
US4383947A (en) * 1981-07-24 1983-05-17 The Upjohn Company Introduction of a fluorine atom
US4416821A (en) * 1982-02-17 1983-11-22 The Upjohn Company Process for preparing 16-methylene steroids
US4618456A (en) * 1984-03-20 1986-10-21 The Upjohn Company Ethynylation of 16-methyl-17-keto steroids
DE3585547D1 (de) * 1984-02-03 1992-04-16 Upjohn Co Steroide mit einer enamid- oder enimidgruppe sowie ihre herstellung.
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
KR960010793B1 (ko) * 1986-10-10 1996-08-08 루쎌 위클라프 소시에떼 아노님 9-알파-히드록시 스테로이드 및 그의 제조방법
US4921638A (en) * 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one

Also Published As

Publication number Publication date
FI882461A (fi) 1988-05-25
ES2052550T3 (es) 1994-07-16
DE3783007T2 (de) 1993-07-01
CA1334844C (en) 1995-03-21
CN1035182C (zh) 1997-06-18
DK313188D0 (da) 1988-06-09
AU607948B2 (en) 1991-03-21
IL84135A0 (en) 1988-03-31
WO1988002753A3 (en) 1988-06-30
NO174748C (no) 1994-06-29
KR960010793B1 (ko) 1996-08-08
EP0263569A2 (de) 1988-04-13
IL84135A (en) 1992-08-18
HUT47130A (en) 1989-01-30
CN1036342C (zh) 1997-11-05
HU204063B (en) 1991-11-28
GR3006576T3 (de) 1993-06-30
AU8106887A (en) 1988-05-06
CN1116208A (zh) 1996-02-07
HUT61568A (en) 1993-01-28
KR890700129A (ko) 1989-03-02
FI95710C (fi) 1996-03-11
NO882075D0 (no) 1988-05-11
PT85891B (pt) 1990-07-31
IE61985B1 (en) 1994-12-14
DK175438B1 (da) 2004-10-18
HU912420D0 (en) 1991-12-30
DK313188A (da) 1988-06-09
IE872722L (en) 1992-04-16
NO882075L (no) 1988-05-11
US5565588A (en) 1996-10-15
WO1988002753A2 (en) 1988-04-21
FI95710B (fi) 1995-11-30
CN87106868A (zh) 1988-04-27
FI882461A0 (fi) 1988-05-25
US5352809A (en) 1994-10-04
EP0263569B1 (de) 1992-12-09
NZ222103A (en) 1990-08-28
PT85891A (en) 1987-11-01
HU211080B (en) 1995-10-30
JPH0826062B2 (ja) 1996-03-13
NO174748B (no) 1994-03-21
JPH01500907A (ja) 1989-03-30
EP0263569A3 (en) 1988-07-20

Similar Documents

Publication Publication Date Title
DE3783007D1 (de) 9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate.
DE3780560D1 (de) Fuehler und verfahren zu dessen herstellung.
DE3682874D1 (de) Pyranoindolizinderivate und verfahren zu ihrer herstellung.
DE3782994D1 (de) Erythromycin-a-derivate und verfahren zu ihrer herstellung.
DE3785163T2 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeurederivate und verfahren zu deren herstellung.
DE3578375D1 (de) Knochenzement und verfahren zu seiner herstellung.
DE3878475D1 (de) Organopolysiloxanemulsion und verfahren zu ihrer herstellung.
DE3482258D1 (de) 2,2-difluorpropionsaeurederivate und verfahren zu ihrer herstellung.
DE3779881D1 (de) Steroid-derivate und verfahren zu ihrer herstellung.
DE3878880T2 (de) Metall-keramik-verbindung und verfahren zu ihrer herstellung.
DE3776920D1 (de) Waessriges praeparat und verfahren zu dessen herstellung.
DE3788205D1 (de) Etikett und Verfahren zu seiner Herstellung.
DE3785694D1 (de) Thiophenderivate und verfahren zu ihrer herstellung.
DE3765181D1 (de) Isocarbacycline und verfahren zu ihrer herstellung.
DE3779946T2 (de) Antibiotikum a42125 und verfahren zu dessen herstellung.
DE3770795D1 (de) Radierer und verfahren zu dessen herstellung.
DE3778517D1 (de) 7-brom-beta-carbolin-derivate und verfahren zu ihrer herstellung.
DE3867957D1 (de) Modifiziertes polytetrafluoraethylen und verfahren zu seiner herstellung.
DE3876259D1 (de) Kondensierte pyrazolderivate und verfahren zu ihrer herstellung.
DE3777245D1 (de) Protein und verfahren zu dessen herstellung.
DE3750182D1 (de) (alpha)-HYDROPEROXYISOPROPYLPHENYL-VERBINDUNGEN UND VERFAHREN ZUR HERSTELLUNG.
DE3765239D1 (de) Acetylketendialkylacetale und verfahren zu ihrer herstellung.
DE3770732D1 (de) Cyclohexandionderivat und verfahren zu seiner herstellung.
DE3867392D1 (de) Phenoxyalkancarbonsaeurederivate und verfahren zu ihrer herstellung.
DE3783285T2 (de) Indikatorzusammensetzung und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: HOECHST MARION ROUSSEL, PUTEAUX, FR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN